According to the article summary, current ALK inhibitors do not inhibit the G1202R mutant of the ALK gene, which is one of the most common mutations. The researchers announced the development of a structural analogue of Alectinib (called JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other mutations. JH-VIII-157-02 is also capable of penetrating the central nervous system of mice.
The researchers are mostly from Harvard Medical School, Danna Farber, and a university in Seoul, Korea. No drug company involvement is yet clear.